Global private equity and venture capital news and research

Auven exits cancer drug developer Spirogen to AstraZeneca arm MedImmune

15 Oct 2013

news_spirogen_molecule_lrgDrug-focused private equity investor Auven Therapeutics has sold cancer-targeting pharmaceutical developer Spirogen to MedImmune in a deal worth up to $240m.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016